Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSN-LFA
- Development stage
- Preclinical
- Lead developer
- Elucida Oncology
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
MSN-LFA is an experimental hybrid nanocarrier system designed for targeted cancer therapy. It consists of mesoporous silica nanoparticles (MSNs) that provide a high surface area and pore volume for drug loading, a lipid coating that enhances physicochemical stability and controls drug release, and folic acid (FA) ligands for active targeting. The system specifically targets the Folate receptor alpha (FRα), which is overexpressed in various malignancies, including aggressive breast cancer (e.g., MCF-7 cells), while remaining low in normal tissues. By utilizing receptor-mediated endocytosis, MSN-LFA improves the intracellular accumulation of chemotherapeutic agents like doxorubicin, thereby increasing cytotoxic efficacy and potentially reducing systemic side effects such as cardiotoxicity.
- Other names
- folic acid-functionalized lipid-coated mesoporous silica nanoparticlesFA-functionalized hybrid MSNsfolate-functionalized lipid-coated MSNs
02
Targets
1C metabolism (One-carbon metabolism)
Beyond the preview
Go deeper on MSN-LFA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSN-LFA.